NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
NeuroPace, Inc. announced it will release its financial results for the third quarter of 2026 after market close on November 12, 2026.
Stocks · News reference
Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
NeuroPace, Inc. announced it will release its financial results for the third quarter of 2026 after market close on November 12, 2026.
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same